Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 5, 2017, Pages 432-442

  Lv, Jicheng ^a,b   Zhang, Hong ^a   Wong, Muh Geot ^b   Jardine, Meg J ^b   Hladunewich, Michelle ^c   Jha, Vivek ^d,e   Monaghan, Helen ^b   Zhao, Minghui ^a   Barbour, Sean ^f   Reich, Heather ^g   Cattran, Daniel ^g   Glassock, Richard ^h   Levin, Adeera ^f   Wheeler, David ⁱ   Woodward, Mark ^b,e,j   Billot, Laurent ^b   Chan, Tak Mao ^k   Liu, Zhi Hong ^l   Johnson, David W ^m   Cass, Alan ^b,n   Feehally, John ^o   Floege, Jürgen ^p   Remuzzi, Giuseppe ^q   Wu, Yangfeng ^r   Agarwal, Rajiv ^s   Wang, Hai Yan ^a   Perkovic, Vlado ^b   more..

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

^l JINLING HOSPITAL   (China)

^m UNIVERSITY OF QUEENSLAND   (Australia)

ⁿ MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^o UNIVERSITY OF LEICESTER   (United Kingdom)

^p RWTH AACHEN UNIVERSITY   (Germany)

^q MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^r PEKING UNIVERSITY   (China)

^s INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN A; METHYLPREDNISOLONE; PLACEBO; RENIN INHIBITOR; GLUCOCORTICOID;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BONE NECROSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY TERMINATION OF CLINICAL TRIAL; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CLINICAL TRIAL; COMPLICATION; GLOMERULONEPHRITIS, IGA; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; GLUCOCORTICOIDS; HUMANS; INFECTION; KIDNEY FAILURE, CHRONIC; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROTEINURIA;

EID: 85027500963     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.9362     Document Type: Article

References (24)

1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402-2414.
2. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479-1485.
3. Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177-3183.
4. Lv J, Zhang H, Zhou Y, Li G, Zou W, Wang H. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton). 2008;13(3):242-246.
5. Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007; 18(6):1880-1888.
6. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857-1863.
7. Cattran DC, Feehally J, Cook HT, et al. Kidney disease: Improving Global Outcomes (KDIGO) glomerulonephritis work group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139-274.
8. Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016;387(10032):2036-2048.
9. Lv J, Xu D, Perkovic V, et al; TESTING Study Group. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012;23(6):1108-1116.
10. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694-3701.
11. Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53(1):26-32.
12. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883-887.
13. Rauen T, Eitner F, Fitzner C, et al; STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225-2236.
14. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
15. Cattran DC, Coppo R, Cook HT, et al; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534-545.
16. Coresh J, Turin TC, Matsushita K, et al; CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014; 311(24):2518-2531.
17. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821-835.
18. Li X, Liu Y, Lv J, et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014;9 (3):484-489.
19. Inker LA, Mondal H, Greene T, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016;68(3):392-401.
20. Barbour SJ, Cattran DC, Kim SJ, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013;84(5): 1017-1024.
21. Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol. 2015;26(9):2248-2258.
22. Fellström BC, Barratt J, Cook H, et al; NEFIGAN Trial Investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389 (10084):2117-2127.
23. Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens. 1987;5(4): 425-433.
24. Smets P, Meyer E, Maddens B, Daminet S. Cushing’s syndrome, glucocorticoids and the kidney. Gen Comp Endocrinol. 2010;169(1):1-10.